Gilead Sciences (NASDAQ:GILD) Given New $77.00 Price Target at Royal Bank of Canada

Gilead Sciences (NASDAQ:GILDGet Rating) had its price target upped by Royal Bank of Canada from $76.00 to $77.00 in a research note published on Tuesday morning, Benzinga reports. The brokerage currently has an outperform rating on the biopharmaceutical company’s stock.

GILD has been the subject of several other research reports. Barclays reduced their price target on shares of Gilead Sciences from $63.00 to $56.00 and set an underweight rating for the company in a research report on Thursday, March 10th. Bank of America lowered their price target on shares of Gilead Sciences from $73.00 to $71.00 and set a neutral rating on the stock in a report on Wednesday, February 2nd. Argus raised shares of Gilead Sciences from a hold rating to a buy rating and set a $75.00 target price on the stock in a research note on Friday, January 28th. Maxim Group decreased their price target on shares of Gilead Sciences from $88.00 to $84.00 in a research note on Thursday, February 3rd. Finally, Truist Financial cut their target price on shares of Gilead Sciences from $77.00 to $75.00 and set a hold rating on the stock in a report on Wednesday, February 2nd. One research analyst has rated the stock with a sell rating, nine have given a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of Hold and a consensus price target of $73.31.

NASDAQ:GILD opened at $61.63 on Tuesday. The firm’s fifty day moving average is $60.63 and its 200-day moving average is $66.26. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.13 and a current ratio of 1.27. Gilead Sciences has a 52 week low of $57.19 and a 52 week high of $74.12. The firm has a market cap of $77.28 billion, a P/E ratio of 12.50, a P/E/G ratio of 0.45 and a beta of 0.40.

Gilead Sciences (NASDAQ:GILDGet Rating) last released its earnings results on Tuesday, February 1st. The biopharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.53 by ($0.84). Gilead Sciences had a net margin of 22.80% and a return on equity of 45.27%. The company had revenue of $7.24 billion for the quarter, compared to analyst estimates of $6.64 billion. During the same quarter in the previous year, the firm earned $2.19 EPS. The firm’s revenue was down 2.4% on a year-over-year basis. As a group, sell-side analysts anticipate that Gilead Sciences will post 6.51 earnings per share for the current year.

The business also recently declared a quarterly dividend, which was paid on Wednesday, March 30th. Investors of record on Tuesday, March 15th were issued a dividend of $0.73 per share. This represents a $2.92 annualized dividend and a yield of 4.74%. The ex-dividend date of this dividend was Monday, March 14th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.71. Gilead Sciences’s dividend payout ratio is presently 59.23%.

In related news, EVP Brett A. Pletcher sold 3,634 shares of Gilead Sciences stock in a transaction dated Friday, March 11th. The stock was sold at an average price of $58.24, for a total transaction of $211,644.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Brett A. Pletcher sold 1,691 shares of Gilead Sciences stock in a transaction dated Wednesday, February 9th. The stock was sold at an average price of $63.89, for a total value of $108,037.99. The disclosure for this sale can be found here. Insiders have sold a total of 19,386 shares of company stock worth $1,283,423 in the last 90 days. 0.16% of the stock is currently owned by insiders.

Large investors have recently made changes to their positions in the business. FSB Premier Wealth Management Inc. acquired a new position in Gilead Sciences in the fourth quarter valued at approximately $28,000. TFO TDC LLC raised its stake in shares of Gilead Sciences by 125.0% during the 3rd quarter. TFO TDC LLC now owns 450 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 250 shares during the period. OLD Second National Bank of Aurora raised its stake in shares of Gilead Sciences by 46.3% during the 3rd quarter. OLD Second National Bank of Aurora now owns 439 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 139 shares during the period. Capital Advisors Ltd. LLC raised its stake in shares of Gilead Sciences by 127.6% during the 4th quarter. Capital Advisors Ltd. LLC now owns 446 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 250 shares during the period. Finally, Mystic Asset Management Inc. acquired a new position in shares of Gilead Sciences during the 4th quarter worth approximately $33,000. 79.00% of the stock is owned by institutional investors.

Gilead Sciences Company Profile (Get Rating)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases.

Further Reading

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.